(a) Define ischemic heart disease. Enumerate four ischemic syndromes. Discuss the pathogenesis of myocardial infarction. Briefly…

Ischemic Heart Disease (IHD) is defined as a state of myocardial impairment resulting from an imbalance between myocardial oxygen supply and demand, most frequently precipitated by coronary atherosclerotic narrowing. The four major clinical ischemic syndromes are chronic stable angina, unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).

Pathogenesis of Myocardial Infarction Myocardial infarction (MI) is initiated when an unstable atheromatous plaque undergoes sudden disruption via fissure, erosion, or intraplaque hemorrhage. Exposure of the thrombogenic subendothelial core triggers immediate platelet adhesion via von Willebrand factor, followed by platelet activation and release of thromboxane A2 and ADP. Concurrently, exposed tissue factor activates the extrinsic coagulation cascade, generating thrombin and cross-linked fibrin. This culminates in an occlusive luminal thrombus. Critical cessation of coronary blood flow halts aerobic glycolysis within seconds. If ischemia persists beyond 20 to 30 minutes, irreversible cellular injury begins in the subendocardium and progresses as a wavefront of coagulative necrosis toward the epicardium over 6 to 12 hours.

Infarct Modification by Reperfusion Timely reperfusion via primary percutaneous coronary intervention or fibrinolytic therapy halts the wavefront of necrosis, preserving ventricular function. However, restoration of blood flow can induce reperfusion injury. Mechanisms include:

• Generation of toxic reactive oxygen species upon reoxygenation.
• Intracellular and mitochondrial calcium overload causing hypercontraction band necrosis.
• Neutrophil infiltration exacerbating microvascular occlusion and inflammation.
• Endothelial swelling and microvascular damage manifesting as the "no-reflow" phenomenon.
• Myocardial stunning (prolonged post-ischemic mechanical dysfunction) and reperfusion arrhythmias.

Pharmacology of Methotrexate and Furosemide Methotrexate: A folate antimetabolite inhibiting dihydrofolate reductase.

• Indications: Autoimmune diseases (rheumatoid arthritis, severe psoriasis), hematological malignancies (acute lymphoblastic leukemia), and solid tumors (choriocarcinoma, osteosarcoma).
• Drug interactions: NSAIDs, probenecid, and penicillins reduce renal tubular clearance of methotrexate, markedly increasing systemic toxicity; co-administration with trimethoprim increases antifolate toxicity.
• Side effects: Bone marrow suppression, oral mucositis, hepatotoxicity, pulmonary fibrosis, and teratogenicity.

Furosemide: A loop diuretic inhibiting the luminal Na+-K+-2Cl- cotransporter in the thick ascending limb of Henle.

• Indications: Acute pulmonary edema, congestive heart failure, nephrotic edema, chronic kidney disease, hypertension, and acute hypercalcemia.
• Drug interactions: Synergistic ototoxicity with aminoglycosides; blunted natriuresis with NSAIDs; hypokalemia potentiates digoxin toxicity and impairs renal lithium clearance.
• Side effects: Hypokalemia, hyponatremia, hypomagnesemia, dehydration, hyperuricemia, and ototoxicity.

Role of CD4 Count and Viral Load in HIV Infection CD4+ T-lymphocyte count is the standard surrogate marker for host immune competence. It determines clinical staging under WHO and CDC systems, defines the risk of opportunistic infections, and dictates the initiation and discontinuation of chemoprophylaxis (such as cotrimoxazole for Pneumocystis jirovecii when CD4 falls below 200 cells/µL).

Plasma viral load (HIV-1 RNA quantitative PCR) reflects the rate of active viral replication and serves as the most accurate predictor of disease progression. Under National AIDS Control Organisation (NACO) guidelines, routine viral load monitoring is the definitive gold standard to evaluate adherence, confirm therapeutic response, and detect early virological failure before immunological or clinical decline occurs.

Antigenic Structure and Diagnosis of Salmonella typhi Salmonella typhi possesses three principal antigens:

• Somatic (O) Antigen: Lipopolysaccharide component of the outer membrane (factors 9 and 12); heat-stable.
• Flagellar (H) Antigen: Proteinaceous flagellin (phase 1 'd'); heat-labile.
• Capsular (Vi) Antigen: Acidic polysaccharide surface antigen enveloping the O antigen; heat-labile.

Diagnostic Implications: The Widal tube agglutination test assesses antibody responses against O and H antigens. A single baseline diagnostic titre (anti-O > 1:160, anti-H > 1:160 in endemic settings) or a four-fold rise in paired sera confirms active enteric fever. Anti-O appears early and wanes quickly, signifying acute infection, whereas anti-H appears later and persists. Surface Vi antigen can mask O agglutination, producing false-negative O titres. Detecting high-titre anti-Vi antibodies by ELISA or agglutination is vital for identifying chronic asymptomatic carriers who harbor the bacilli in the gallbladder.

A comprehensive public health approach requires integrating emergency myocardial reperfusion networks to curb India's escalating cardiovascular burden, sustaining universal viral load surveillance under NACO for HIV, and deploying Typhoid Conjugate Vaccines (TCV) combined with strict carrier surveillance to disrupt endemic enteric transmission.